• Explore /
  • Poster
  • / Regomune: A phase II study of regorafenib + avelumab in solid tumors—Results of the biliary tract cancer (BTC) cohort.

Regomune: A phase II study of regorafenib + avelumab in solid tumors—Results of the biliary tract cancer (BTC) cohort.

Abstract Poster

Authors

null

Sophie Cousin

Medical Oncology, Institute Bergonié, Bordeaux, France

Sophie Cousin , Carine A. Bellera , Jean Philippe Guégan , Thibault Mazard , Carlos A. Gomez-Roca , Jean Philippe Metges , Coralie Cantarel , Antoine Adenis , Iphigenie Korakis , Pierre-guillaume Poureau , Mariella spalato-Ceruso , Kevin Bourcier , Michèle Kind , Isabelle Soubeyran , Alban Bessede , Antoine Italiano

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer

Clinical Trial Registration Number

NCT03475953

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 4096)

DOI

10.1200/JCO.2021.39.15_suppl.4096

Abstract #

4096

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Sophie Cousin

First Author: Thorsten Oliver Goetze

First Author: Junho Kang

Poster

2019 ASCO Annual Meeting

Final analysis of phase II trial of regorafenib (REG) in refractory advanced biliary cancers (BC).

Final analysis of phase II trial of regorafenib (REG) in refractory advanced biliary cancers (BC).

First Author: Dae Won Kim